Overview


The Opioid Dependence Treatment Market encompasses the global industry focused on medications and therapies for opioid use disorder (OUD), including treatments like buprenorphine, methadone, and naltrexone, as well as behavioral therapy and telehealth solutions.

According to FutureWise analysis, the Opioid Dependence Treatment Market in 2026 is US$3.67 billion and is expected to reach US$8.14 billion by 2036 at a CAGR of 8.29%. The growth in opioid misuse treatment stems from increased awareness, better access to medication-assisted treatment (MAT), and the rising use of buprenorphine and methadone. Government initiatives and the expansion of telehealth also enhance treatment outcomes globally.

Growth Drivers:

  • Rising prevalence of opioid use disorder (OUD) globally
  • Increasing government funding and supportive regulatory policies
  • Growing adoption of medication-assisted treatment (MAT)
  • Expansion of telehealth and digital addiction care platforms
  • Increasing awareness and destigmatization of substance use disorders

Key Trends:

  • Expansion of telemedicine and digital therapeutics for remote addiction treatment and support
  • Increasing use of long-acting injectable and implantable formulations to improve patient adherence
  • Growing integration of behavioral therapies with medication-assisted treatment (MAT)
  • Rising focus on personalized and data-driven care models using AI and analytics
  • Enhanced government initiatives and public-private partnerships for prevention and treatment programs

Market Segmentation and Key Players:

The Opioid Dependence Treatment Market is segmented by drug class into Buprenorphine, Naloxone, and Methadone, representing the core pharmacological therapies used in medication-assisted treatment (MAT). Based on distribution channel, the market is categorized into Retail Pharmacies, Hospitals, and Rehabilitation Centres, reflecting the primary points of access for patients undergoing treatment. Geographically, the market is divided into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa to assess regional demand patterns and growth potential. Comprehensive segmentation details are provided in the Segmentation section below.

Major companies operating in the Opioid Dependence Treatment Market include Reckitt Benckiser Pharmaceuticals Inc., Mylan (Viatris), and Dr. Reddy’s Laboratories.

Research Methodology:

The research methodology for the Opioid Dependence Treatment Market, conducted by FutureWise Research, combines primary interviews with industry experts and secondary analysis of company reports, regulatory data, and published studies. FutureWise Research employs market sizing, segmentation, and forecasting models that are validated through data triangulation. This approach ensures accurate insights into market trends, growth drivers, and regional opportunities.

  • Reckitt Benckiser Pharmaceuticals Inc.
  • Mylan
  • Dr. Reddy's Laboratories
  • ADAPT Pharma, Inc.
  • LUMITOS AG
  • Orexo AB
  • Indivior PLC
  • Camurus AB
  • Alkermes
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Opioid Dependence Treatment :

Mylan (Viatris)

Viatris, formerly known as Mylan, has reached a nationwide multistate settlement worth up to $335 million over nine years to address legal claims related to opioids. The company will make annual payments ranging from approximately $27.5 million to $40 million to support state and local initiatives focused on responding to the opioid crisis.

Dr. Reddy's Laboratories

  • Dr. Reddy’s relaunched its generic buprenorphine/naloxone sublingual film (equivalent to Suboxone) in the U.S. in February 2019 after a favorable appellate decision lifted an injunction that had previously blocked sales. The firm originally launched "at-risk" in June 2018 before facing legal setbacks.
  • In June 2022, Dr. Reddy's reached a settlement with Indivior and Aquestive, resolving all patent and antitrust claims. The agreement led to the dismissal of all pending cases and included a payment arrangement totaling $72 million to be completed by March 2024.

By Drug Class

  • Buprenorphine
  • Naloxone
  • Methadone

By Sales Channel

  • Retail Pharmacies
  • Hospitals
  • Rehabilitation Centres

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Here’s a regional view of where the most progress is happening:

The Asia Pacific region is at the forefront of opioid dependence treatment market development. This growth is fueled by increased awareness, improved healthcare infrastructure, and significant government investments.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrant

 

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global Opioid Dependence Treatment Market by Drug Class, by Sales Channel, and by Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Opioid Dependence Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Opioid Dependence Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Opioid Dependence Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Opioid Dependence Treatment Market, By Drug Class Historical Analysis and Forecast 2026-2036 (USD Million)
    •   1. Buprenorphine
        2. Naloxone
        3. Methadone

  • 8.   Opioid Dependence Treatment Market, By Sales Channel Historical Analysis and Forecast 2026-2036 (USD Million)
    •   1. Retail Pharmacies
        2. Hospitals
        3. Rehabilitation Centres

  • 9.   North America Opioid Dependence Treatment Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2026-2036

  • 10.   Latin America Opioid Dependence Treatment Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2026-2036

  • 11.   Europe Opioid Dependence Treatment Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2026-2036

  • 12.   Asia Pacific Opioid Dependence Treatment Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2026-2036

  • 13.   Middle East and Africa Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2026-2036

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Reckitt Benckiser Pharmaceuticals Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Mylan
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Dr. Reddy's Laboratories
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. ADAPT Pharma, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. LUMITOS AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Orexo AB
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Indivior PLC
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Camurus AB
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Alkermes
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Teva Pharmaceutical Industries Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Hikma Pharmaceuticals PLC
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

FAQ


Global opioid addiction is rising, leading to increased awareness and accessibility of treatment programs. There have been regulatory approvals for non-opioid pain management and long-acting therapies, as well as the integration of telehealth and AI-based monitoring systems.

Legal and patent disputes affecting drug availability,

High costs of long-acting treatments,

Limited access in developing regions,

Stigma surrounding opioid dependence and its treatment.

The opioid dependence treatment market includes medications, therapies, and supportive programs designed to assist individuals in managing and overcoming opioid use disorder (OUD). Treatment options may consist of opioid agonists, antagonists, non-opioid alternatives, counseling, and digital support platforms.

Medication-Assisted Treatment (MAT): Methadone, Buprenorphine, and Naltrexone.

Non-opioid Pain Management: Emerging medications aimed at reducing opioid reliance.

Behavioral Therapies: Including counseling and cognitive-behavioral therapy (CBT).

Digital Health Solutions: Such as telehealth, mobile applications, and AI-based relapse prevention.

Related Market

Opioid-Induced Respiratory Depression Market

Read More

Opioid Use Disorder (OUD) Market

Read More

Opioid Induced Side Effects Treatment Market

Read More
Partner

Our Clients